| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Advances in the understanding and management of myeloproliferative disorders
|
Skoda, Radek
|
|
2007
|
|
s68 |
p. 2-4
|
article
|
| 2 |
Essential thrombocythaemia treatment options: addressing patient-specific needs
|
Birgegård, Gunnar
|
|
2007
|
|
s68 |
p. 27-31
|
article
|
| 3 |
Evolving management of essential thrombocythaemia
|
Barbui, Tiziano
|
|
2007
|
|
s68 |
p. 22-23
|
article
|
| 4 |
Implications of the consensus definition of clinical resistance and intolerance to hydroxyurea for clinical practice
|
Reilly, John T.
|
|
2007
|
|
s68 |
p. 32-34
|
article
|
| 5 |
Myelofibrosis: biology and treatment options
|
Cervantes, Francisco
|
|
2007
|
|
s68 |
p. 13-17
|
article
|
| 6 |
Myeloproliferative disorders: a time of new definitions Outflow from New Horizons in Haematology Meeting, 9–10 March 2007
|
Skoda, Radek
|
|
2007
|
|
s68 |
p. 1
|
article
|
| 7 |
New consensus: a unified definition of clinical resistance and/or intolerance to hydroxyurea in essential thrombocythaemia
|
Barosi, Giovanni
|
|
2007
|
|
s68 |
p. 24-26
|
article
|
| 8 |
Options in the management of essential thrombocythaemia
|
Griesshammer, Martin
|
|
2007
|
|
s68 |
p. 35-39
|
article
|
| 9 |
Phenotype and genotype in the myeloproliferative disorders
|
Spivak, Jerry L.
|
|
2007
|
|
s68 |
p. 9-12
|
article
|
| 10 |
Unanswered questions in polycythaemia vera
|
Finazzi, Guido
|
|
2007
|
|
s68 |
p. 18-21
|
article
|
| 11 |
Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders
|
Skoda, Radek
|
|
2007
|
|
s68 |
p. 5-8
|
article
|
Journal description